Leiden, The Netherlands, November 5, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the upcoming oral presentation of interim results from its ongoing Phase II clinical trial (ADVANCE II, Clintrials.gov: NCT03697707) at the virtual 62nd ASH Annual Meeting and Exposition on December 5, 2020. The Interim data on both primary and secondary endpoints of the trial highlight the potential of the company’s lead vaccine candidate, DCP-001, to improve the treatment options for patients with Acute Myeloid Leukemia (AML) in the post-remission setting. The study continues to enroll patients at the higher of two vaccine doses tested and updated data will be shown at ASH.
The oral presentation entitled “Conversion from MRD positive to negative status in AML patients in CR1 after treatment with an Allogeneic Leukemia-derived Dendritic Cell Vaccine” will be presented by Prof. Dr. Arjan van de Loosdrecht from the Department of Hematology at Amsterdam UMC, Amsterdam, The Netherlands, and Principal Investigator for the study.
The accepted abstract is listed below and is now available online on the ASH website: https://ash.confex.com/ash/2020/webprogram/Paper139266.html
The Phase II study ADVANCE II is a European collaboration between several hospitals and companies, the AML-VACCiN consortium, and is supported by a European Horizon grant.
Oral Presentation Details:
Presentation Title: #168: Conversion from MRD positive to negative status in AML patients in CR1 after treatment with an Allogeneic Leukemia-derived Dendritic Cell Vaccine
Session Title: Acute Myeloid Leukemia: Novel therapy, excluding transplantation: Advances in immunotherapeutics for management of AML
Session Date: Saturday, December 5, 2020
Presentation Time: 12:45 PM EST
Presenter: Prof. Dr. Arjan van de Loosdrecht – Department of Hematology, VUmc
About DCprime
DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after or in conjunction with standard of care therapy to delay or prevent disease recurrence. Our lead product is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse. We are pursuing similar vaccination approaches for solid tumors. We believe relapse vaccines will improve survival by putting the patient’s immune system back in control. For more information, please visit: https://dcprime.com/
Contact Information:
DCprime BV
Dr. Erik Manting, CEO
Phone: +31 713322627
Email: e.manting@dcprime.com
Media Contact:
Mario Brkulj or Nicholas Chang
MacDougall
Phone: +49 175 5711562 or +1 781 235 3060
E-Mail: dcprime@macbiocom.com